[go: up one dir, main page]

CN1751047A - 可用于治疗的三唑化合物 - Google Patents

可用于治疗的三唑化合物 Download PDF

Info

Publication number
CN1751047A
CN1751047A CNA2004800047089A CN200480004708A CN1751047A CN 1751047 A CN1751047 A CN 1751047A CN A2004800047089 A CNA2004800047089 A CN A2004800047089A CN 200480004708 A CN200480004708 A CN 200480004708A CN 1751047 A CN1751047 A CN 1751047A
Authority
CN
China
Prior art keywords
compound
mmol
chloro
preparation
bipyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800047089A
Other languages
English (en)
Chinese (zh)
Inventor
J·S·布赖恩斯
P·S·约翰逊
T·里克曼斯
A·斯托比
R·J·拉塞尔
C·P·韦曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1751047A publication Critical patent/CN1751047A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800047089A 2003-02-19 2004-02-09 可用于治疗的三唑化合物 Pending CN1751047A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0303852.8A GB0303852D0 (en) 2003-02-19 2003-02-19 Triazole compounds useful in therapy
GB0303852.8 2003-02-19
GB0317227.7 2003-07-23

Publications (1)

Publication Number Publication Date
CN1751047A true CN1751047A (zh) 2006-03-22

Family

ID=9953327

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800047089A Pending CN1751047A (zh) 2003-02-19 2004-02-09 可用于治疗的三唑化合物

Country Status (11)

Country Link
CN (1) CN1751047A (fr)
AR (1) AR043210A1 (fr)
CL (1) CL2004000293A1 (fr)
GB (1) GB0303852D0 (fr)
GT (1) GT200400020A (fr)
NL (1) NL1025527C2 (fr)
PA (1) PA8596101A1 (fr)
PE (1) PE20050222A1 (fr)
TW (1) TW200500367A (fr)
UY (1) UY28201A1 (fr)
WO (1) WO2004074291A1 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216304A (zh) * 2008-11-18 2011-10-12 弗·哈夫曼-拉罗切有限公司 二氢四氮杂苯并薁的烷基环己基醚
CN102766674A (zh) * 2012-07-25 2012-11-07 辉源生物科技（上海）有限公司 食蟹猴抗利尿激素受体v1a拮抗剂筛选平台的建立
CN102812011A (zh) * 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
CN102822176A (zh) * 2010-03-31 2012-12-12 霍夫曼-拉罗奇有限公司 芳基-环己基-四氮杂苯并[e]薁
CN102834396A (zh) * 2010-04-13 2012-12-19 霍夫曼-拉罗奇有限公司 作为血管升压素拮抗剂的芳基-/杂芳基-环己烯基-四氮杂苯并[e]薁
CN102858778A (zh) * 2010-04-26 2013-01-02 霍夫曼-拉罗奇有限公司 杂联芳基-环己基-四氮杂苯并[e]薁
CN102858776A (zh) * 2010-04-21 2013-01-02 霍夫曼-拉罗奇有限公司 作为血管升压素V1a受体拮抗剂的杂芳基-环己基-四氮杂苯并[e]薁
CN102884065A (zh) * 2010-05-10 2013-01-16 霍夫曼-拉罗奇有限公司 杂芳基-环己基-四氮杂苯并[e]薁
CN103080087A (zh) * 2010-07-01 2013-05-01 贝林格尔.英格海姆国际有限公司 哌啶衍生物及其用于治疗代谢紊乱的用途
CN103827121A (zh) * 2011-09-26 2014-05-28 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的氧基-环己基-4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]薁
CN103842365A (zh) * 2011-10-05 2014-06-04 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的环己基-4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]薁
US10633384B2 (en) 2012-06-13 2020-04-28 Hoffmann-La Roche Inc. Diazaspirocycloalkane and azaspirocycloalkane
US10640472B2 (en) 2015-09-04 2020-05-05 Hoffman-La Roche Inc. Phenoxymethyl derivatives
US10647719B2 (en) 2015-09-24 2020-05-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10654857B2 (en) 2014-03-26 2020-05-19 Hoffman-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
CN111170983A (zh) * 2019-12-26 2020-05-19 中国农业大学 一种苄硫基乙酰胺类化合物及其制备方法与应用
US10669285B2 (en) 2014-03-26 2020-06-02 Hoffmann-La Roche Inc. Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10669268B2 (en) 2012-09-25 2020-06-02 Hoffmann-La Roche Inc. Bicyclic derivatives
US10676446B2 (en) 2015-04-10 2020-06-09 Hoffmann-La Roche Inc. Bicyclic quinazolinone derivatives
US10738053B2 (en) 2015-09-24 2020-08-11 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10787459B2 (en) 2015-09-24 2020-09-29 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10800786B2 (en) 2015-09-24 2020-10-13 Hoffman-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10849881B2 (en) 2013-11-26 2020-12-01 Hoffmann-La Roche Inc. Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl
US10882857B2 (en) 2017-03-16 2021-01-05 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10913745B2 (en) 2013-03-12 2021-02-09 Hoffmann-La Roche Inc. Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
US11059794B2 (en) 2017-03-16 2021-07-13 Hoffmann-La Roche Inc. Heterocyclic compounds useful as dual ATX/CA inhibitors
CN114644635A (zh) * 2020-12-21 2022-06-21 上海济煜医药科技有限公司 三氮唑类三并环衍生物及其制备方法和应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
DE102004001871A1 (de) * 2004-01-14 2005-09-01 Bayer Healthcare Ag Tricyclische Benzazepin-Derivate und ihre Verwendung
BRPI0514458A (pt) 2004-08-25 2008-06-10 Pfizer triazolbenzodiazepinas e seu uso como antagonistas de vasopressina
JP2008539220A (ja) * 2005-04-26 2008-11-13 ファイザー・リミテッド バソプレシンアンタゴニストとしてのトリアゾール誘導体
CA2741018A1 (fr) 2008-11-13 2010-05-20 F. Hoffmann-La Roche Ag Spiro-5,6-dihydro-4h-2,3,5,10b-tetraza-benzo[e]azulenes
SI2370441T1 (sl) 2008-11-28 2013-12-31 F. Hoffmann-La Roche Ag Arilcikloheksiletri dihidrotetraazabenzoazulenov za uporabo kot antagonisti receptorja vazopresina V1A
TW201100427A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted heterocyclic compounds
CA2813911A1 (fr) 2010-10-07 2012-04-12 Takeda Pharmaceutical Company Limited Derives de 1,4-oxazepane
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
JP6427192B2 (ja) * 2013-08-19 2018-11-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 位相変位睡眠障害を処置するためのＶ１ａアンタゴニスト
KR102384629B1 (ko) 2013-12-05 2022-04-11 에프. 호프만-라 로슈 아게 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성
US11186577B2 (en) * 2017-06-05 2021-11-30 Blackthorn Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) * 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823475D0 (en) * 1988-10-06 1988-11-16 Merck Sharp & Dohme Chemical compounds
US5438035A (en) * 1994-06-24 1995-08-01 American Cyanamid Company Methods for controlling undesirable plant species with benzodiazepine compounds
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
PT1021444E (pt) * 1996-11-01 2004-02-27 Wyeth Corp Derivados 3-carboxamida de 5h-pirrolo¬2,1-c|¬1,4|-benzodiazepinas
NZ512960A (en) * 1999-01-19 2004-01-30 Ortho Mcneil Pharm Inc Tricyclic benzodiazepines as vasopressin receptor antagonists
US7109193B2 (en) * 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216304B (zh) * 2008-11-18 2014-07-09 弗·哈夫曼-拉罗切有限公司 二氢四氮杂苯并薁的烷基环己基醚
CN102216304A (zh) * 2008-11-18 2011-10-12 弗·哈夫曼-拉罗切有限公司 二氢四氮杂苯并薁的烷基环己基醚
CN102812011A (zh) * 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
CN102822176A (zh) * 2010-03-31 2012-12-12 霍夫曼-拉罗奇有限公司 芳基-环己基-四氮杂苯并[e]薁
CN102834396A (zh) * 2010-04-13 2012-12-19 霍夫曼-拉罗奇有限公司 作为血管升压素拮抗剂的芳基-/杂芳基-环己烯基-四氮杂苯并[e]薁
CN102834396B (zh) * 2010-04-13 2016-06-01 霍夫曼-拉罗奇有限公司 作为血管升压素拮抗剂的芳基-/杂芳基-环己烯基-四氮杂苯并[e]薁
CN102858776B (zh) * 2010-04-21 2016-01-20 霍夫曼-拉罗奇有限公司 作为血管升压素V1a受体拮抗剂的杂芳基-环己基-四氮杂苯并[e]薁
CN102858776A (zh) * 2010-04-21 2013-01-02 霍夫曼-拉罗奇有限公司 作为血管升压素V1a受体拮抗剂的杂芳基-环己基-四氮杂苯并[e]薁
TWI419890B (zh) * 2010-04-21 2013-12-21 Hoffmann La Roche 雜芳基-環己基-四氮雜苯并［ｅ］薁
CN102858778A (zh) * 2010-04-26 2013-01-02 霍夫曼-拉罗奇有限公司 杂联芳基-环己基-四氮杂苯并[e]薁
TWI419892B (zh) * 2010-05-10 2013-12-21 Hoffmann La Roche 雜芳基-環己基-四氮雜苯并［ｅ］薁
CN102884065A (zh) * 2010-05-10 2013-01-16 霍夫曼-拉罗奇有限公司 杂芳基-环己基-四氮杂苯并[e]薁
CN102884065B (zh) * 2010-05-10 2015-11-25 霍夫曼-拉罗奇有限公司 杂芳基-环己基-四氮杂苯并[e]薁
CN103080087A (zh) * 2010-07-01 2013-05-01 贝林格尔.英格海姆国际有限公司 哌啶衍生物及其用于治疗代谢紊乱的用途
CN103827121A (zh) * 2011-09-26 2014-05-28 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的氧基-环己基-4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]薁
CN103827121B (zh) * 2011-09-26 2016-08-03 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的氧基-环己基-4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]薁
CN103842365B (zh) * 2011-10-05 2017-06-23 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的环己基‑4H，6H‑5‑氧杂‑2，3，10b‑三氮杂‑苯并[e]薁
CN103842365A (zh) * 2011-10-05 2014-06-04 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的环己基-4H,6H-5-氧杂-2,3,10b-三氮杂-苯并[e]薁
US10633384B2 (en) 2012-06-13 2020-04-28 Hoffmann-La Roche Inc. Diazaspirocycloalkane and azaspirocycloalkane
CN102766674A (zh) * 2012-07-25 2012-11-07 辉源生物科技（上海）有限公司 食蟹猴抗利尿激素受体v1a拮抗剂筛选平台的建立
US10669268B2 (en) 2012-09-25 2020-06-02 Hoffmann-La Roche Inc. Bicyclic derivatives
US10913745B2 (en) 2013-03-12 2021-02-09 Hoffmann-La Roche Inc. Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors
US10849881B2 (en) 2013-11-26 2020-12-01 Hoffmann-La Roche Inc. Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl
US11098048B2 (en) 2014-03-26 2021-08-24 Hoffmann-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10669285B2 (en) 2014-03-26 2020-06-02 Hoffmann-La Roche Inc. Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10654857B2 (en) 2014-03-26 2020-05-19 Hoffman-La Roche Inc. Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
US10676446B2 (en) 2015-04-10 2020-06-09 Hoffmann-La Roche Inc. Bicyclic quinazolinone derivatives
US11352330B2 (en) 2015-09-04 2022-06-07 Hoffmann-La Roche Inc. Phenoxymethyl derivatives
US10640472B2 (en) 2015-09-04 2020-05-05 Hoffman-La Roche Inc. Phenoxymethyl derivatives
US10738053B2 (en) 2015-09-24 2020-08-11 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10787459B2 (en) 2015-09-24 2020-09-29 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10800786B2 (en) 2015-09-24 2020-10-13 Hoffman-La Roche Inc. Bicyclic compounds as ATX inhibitors
US10647719B2 (en) 2015-09-24 2020-05-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10889588B2 (en) 2015-09-24 2021-01-12 Hoffmann-La Roche Inc. Bicyclic compounds as dual ATX/CA inhibitors
US10882857B2 (en) 2017-03-16 2021-01-05 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
US11059794B2 (en) 2017-03-16 2021-07-13 Hoffmann-La Roche Inc. Heterocyclic compounds useful as dual ATX/CA inhibitors
US11673888B2 (en) 2017-03-16 2023-06-13 Hoffmann-La Roche Inc. Bicyclic compounds as ATX inhibitors
CN111170983B (zh) * 2019-12-26 2021-07-09 中国农业大学 一种苄硫基乙酰胺类化合物及其制备方法与应用
CN111170983A (zh) * 2019-12-26 2020-05-19 中国农业大学 一种苄硫基乙酰胺类化合物及其制备方法与应用
CN114644635A (zh) * 2020-12-21 2022-06-21 上海济煜医药科技有限公司 三氮唑类三并环衍生物及其制备方法和应用
WO2022135335A1 (fr) * 2020-12-21 2022-06-30 上海济煜医药科技有限公司 Dérivé tricyclique de triazole et son procédé de préparation et son application
CN114644635B (zh) * 2020-12-21 2023-02-03 上海济煜医药科技有限公司 三氮唑类三并环衍生物及其制备方法和应用

Also Published As

Publication number Publication date
GT200400020A (es) 2004-09-21
CL2004000293A1 (es) 2005-01-07
NL1025527C2 (nl) 2005-03-14
TW200500367A (en) 2005-01-01
UY28201A1 (es) 2004-09-30
PE20050222A1 (es) 2005-04-13
GB0303852D0 (en) 2003-03-26
NL1025527A1 (nl) 2004-08-23
AR043210A1 (es) 2005-07-20
WO2004074291A1 (fr) 2004-09-02
PA8596101A1 (es) 2005-08-04

Similar Documents

Publication Publication Date Title
CN1751047A (zh) 可用于治疗的三唑化合物
CN1058710C (zh) 苯甲酰胺衍生物及其制法、用途和含其的药物组合物
CN1254474C (zh) 作为多巴胺D<sub>3</sub>受体调节剂(精神抑制药)的四氢苯并氮杂䓬衍生物
CN100338044C (zh) Hiv蛋白酶抑制剂、含有它们的组合物、其药物应用及其合成原料
CN1273469C (zh) 作为保胎用催产素受体拮抗剂的三环二氮杂䓬
CN1273128C (zh) 取代的n－[(氨基亚氨基甲基或氨基甲基)苯基]丙基酰胺
CN1708493A (zh) 选择的cgrp拮抗剂、其制法及作为药物的用途
CN1040748C (zh) 苯并吖庚因衍生物及其药物组合物和中间体
CN1620294A (zh) 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
CN1678586A (zh) 取代的喹啉ccr5受体拮抗剂
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1688583A (zh) 用作治疗醛固酮介导的病症的药物的有机化合物
CN1713907A (zh) 作为二肽酰肽酶iv抑制剂的n－取代的吡咯烷衍生物
CN101048412A (zh) 哌啶基氨基－噻吩并[2,3－d]嘧啶化合物
CN1228087A (zh) 取代的嘧啶衍生物和它们的药物用途
CN1407985A (zh) 用作钾通道抑制剂的杂环二氢嘧啶
CN1608061A (zh) 治疗用的异喹啉化合物
CN1556807A (zh) 化合物
CN1823068A (zh) 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物
CN1533387A (zh) 1-苯基磺酰基-1,3-二氢-2h-吲哚-2-酮衍生物,其制备及其治疗应用
CN1575284A (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN101031559A (zh) 氨基环脲衍生物和其制法及作为激酶抑制剂的医药用途
CN1929737A (zh) Hiv整合酶抑制剂
CN1653070A (zh) 作为糖原磷酸化酶抑制剂的杂环酰胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084666

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20060322

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1084666

Country of ref document: HK